Advaxis, Inc. Enrolls Patients To Cervical Cancer Vaccine Trial

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--May 2, 2006--The first cancer patients to be treated with an engineered live Listeria vaccine were dosed in Advaxis Inc. (OTCBB: ADXS - News) Phase I/II clinical trial of Lovaxin C, a Listeria-based therapeutic cancer vaccine developed to treat cervical cancer. Several additional patients are being screened. The trial, taking place in Serbia, Israel and Mexico, will enroll 20 cervical cancer patients and is expected to last approximately six months, with the fundamental objective to demonstrate the safety of Lovaxin C.